-
Something wrong with this record ?
Effects of melanotan II, a melanocortin agonist, on grooming and exploration in rats after repeated restraint/immobilization
V Klenerova, I Krejci, P Sida, Z Hlinak, S Hynie
Language English Country Ireland
NLK
ScienceDirect (archiv)
from 1993-01-01 to 2009-12-31
- MeSH
- alpha-MSH analogs & derivatives pharmacology MeSH
- Behavior, Animal MeSH
- Peptides, Cyclic pharmacology MeSH
- Restraint, Physical MeSH
- Rats MeSH
- Melanocortins antagonists & inhibitors MeSH
- Exploratory Behavior physiology drug effects MeSH
- Grooming physiology drug effects MeSH
- Motor Activity drug effects MeSH
- Rats, Wistar MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
2mg/kg melanotan II (MTII, administered i.p.), a cyclic peptide analog of alpha-melanocyte stimulating hormone, at a single dose increased grooming in naive rats placed in an unfamiliar open-field device without changing locomotion or rearing. Male rats exposed to restraint/immobilization stress (IS) for 1h on three consecutive days displayed increased grooming after the second stressor exposure, compared to pre-stress levels. MTII, administered to the rats after IS, enhanced the grooming response compared both to the pre- and post-stress values. The increase was greatest after the first dose and declined over the following two applications. As to the locomotion of rats in the entire experimental space, IS reduced the distance moved only after the first two stressor exposures; MTII did not influence these alterations. Locomotion in the central part of arena was not reduced by the stressor or by MTII, on the contrary, there was an increase in both groups after the third intervention. The only observed change in rearing was an increase in the MTII group after the third restraint exposure. Thus, MTII selectively increased grooming without markedly affecting the spatio-temporal structure of locomotor behavior in the open-field. The decline of MTII enhanced grooming over the three test days may be interpreted in terms of adaptation to the stressor and of the developing tolerance to the peptide.
- 000
- 03109naa 2200433 a 4500
- 001
- bmc11003204
- 003
- CZ-PrNML
- 005
- 20111210202238.0
- 008
- 110225s2008 ie e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Klenerová, Věra, $d 1940- $7 nlk19990073368
- 245 10
- $a Effects of melanotan II, a melanocortin agonist, on grooming and exploration in rats after repeated restraint/immobilization / $c V Klenerova, I Krejci, P Sida, Z Hlinak, S Hynie
- 314 __
- $a Laboratory of Biochemical Neuropharmacology, Medical Biochemistry, First Faculty of Medicine, Charles University in Prague, Albertov 4, 128 00 Prague 2, Czech Republic.
- 520 9_
- $a 2mg/kg melanotan II (MTII, administered i.p.), a cyclic peptide analog of alpha-melanocyte stimulating hormone, at a single dose increased grooming in naive rats placed in an unfamiliar open-field device without changing locomotion or rearing. Male rats exposed to restraint/immobilization stress (IS) for 1h on three consecutive days displayed increased grooming after the second stressor exposure, compared to pre-stress levels. MTII, administered to the rats after IS, enhanced the grooming response compared both to the pre- and post-stress values. The increase was greatest after the first dose and declined over the following two applications. As to the locomotion of rats in the entire experimental space, IS reduced the distance moved only after the first two stressor exposures; MTII did not influence these alterations. Locomotion in the central part of arena was not reduced by the stressor or by MTII, on the contrary, there was an increase in both groups after the third intervention. The only observed change in rearing was an increase in the MTII group after the third restraint exposure. Thus, MTII selectively increased grooming without markedly affecting the spatio-temporal structure of locomotor behavior in the open-field. The decline of MTII enhanced grooming over the three test days may be interpreted in terms of adaptation to the stressor and of the developing tolerance to the peptide.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a chování zvířat $7 D001522
- 650 _2
- $a pátrací chování $x fyziologie $x účinky léků $7 D005106
- 650 _2
- $a péče o zevnějšek u zvířat $x fyziologie $x účinky léků $7 D006120
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melanokortiny $x antagonisté a inhibitory $7 D053486
- 650 _2
- $a pohybová aktivita $x účinky léků $7 D009043
- 650 _2
- $a cyklické peptidy $x farmakologie $7 D010456
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a fyzické omezení $7 D012149
- 650 _2
- $a alfa-MSH $x analogy a deriváty $x farmakologie $7 D000521
- 700 1_
- $a Krejčí, Ivan $7 xx0097183
- 700 1_
- $a Šída, Pavel. $7 xx0181079
- 700 1_
- $a Hliňák, Zdeněk $7 xx0074045
- 700 1_
- $a Hynie, Sixtus, $d 1933- $7 jk01043454
- 773 0_
- $t Neuroscience Letters $w MED00003507 $g Roč. 432, č. 3 (2008), s. 202-205 $x 0304-3940
- 910 __
- $a ABA008 $b x $y 7
- 990 __
- $a 20110413120333 $b ABA008
- 991 __
- $a 20110413120339 $b ABA008
- 999 __
- $a ok $b bmc $g 830559 $s 695197
- BAS __
- $a 3
- BMC __
- $a 2008 $b 432 $c 3 $d 202-205 $i 0304-3940 $m Neuroscience letters $n Neurosci. lett. $x MED00003507
- LZP __
- $a 2011-2B/ipme